GlassScriptPhysician profile
David Bruce Winmill
NPI 1891715439
$641.59
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $380 · 2023: $27.21 · 2024: $50.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $77.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $77.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $114.43 | 2021-2022 | |
| Dexcom, INC. | $91.19 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $77.30 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.91 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $38.75 | 2021-2022 | |
| Abbott Laboratories | $38.23 | 2022 | |
| Lilly USA, LLC | $38.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $36.14 | 2022 | |
| Abbvie INC. | $25.31 | 2022 | |
| Zealand Pharma US, INC. | $22.75 | 2021 | |
| Medtronic, INC. | $21.14 | 2022 | |
| Mannkind Corporation | $14.74 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.07 | 2022 | |
| Amarin Pharma, INC. | $12.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.66 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Winmill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.